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consistently associated with measures of function and disability. Most
closely associated with function measures were: pain affecting sleep,
for WOMAC function; pain catastrophizing, for Late Life basic function,
chair stand time, and disability; and pain after 20 m walk, for Late Life
advanced function. These ﬁndings suggest that different aspects of the
pain experience in knee OA may have unique relationships with function
and disability. Ultimately, speciﬁc multidisciplinary attention to aspects
such as the impact of pain on sleep and pain catastrophizing may be
a more meaningful approach for the person with painful knee OA, and
potentially have greater impact on function and disability over time.
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Purpose: Better understanding of patients’ perceptions of osteoarthritis
(OA) severity can improve disease management. However, in clinical
practice, categorizing patients as having mild, moderate, or severe OA is
not straightforward.
Purpose: To evaluate the association of patient-reported OA severity
with other patient-reported outcomes in a European population using
the Adelphi Disease Speciﬁc Programme for OA (OA DSP VII, 2008).
Methods: OA severity was rated by patients based on the question “How
bad would you say your arthritis is now?” with potential responses
of “mild,” “moderate,” and “severe.” Other patient-reported outcomes
included; a pain visual analogue scale (0 = no pain, 100 = worst
possible pain); questions on activities of daily living (1 = no difﬁculty,
2 = some difﬁculty, 3 = much difﬁculty, 4 = unable to do); and the
EuroQol health status instrument (EQ-5D). Data on productivity were
captured using the Work Productivity and Activity Impairment scale
(WPAI). Associations between OA severity and other outcomes were
evaluated using descriptive and regression analyses.
Results: Data were available from 1739 patients (63.1% female, mean age
64 years) from France, Germany, Italy, Spain, and the United Kingdom.
OA severity was rated as mild, moderate and severe by 24.5%, 56.4%,
and 19.2% of the patients, respectively. There was an overall association
between patient-rated OA severity and age (p < 0.05). Greater patient-
reported OA severity was associated with higher pain scores; 28.3, 49.9,
and 69.2 for mild, moderate and severe OA, respectively (p < 0.05 for
pairwise comparisons). As patient-reported OA severity increased, so did
functional impairment as indicated by greater difﬁculty in performing 9
basic and 3 instrumental activities of daily living. After adjustment for
gender, the difﬁculty score was greater than 1 at each OA severity level
for every item of functional ability (lower bounds of the 95% conﬁdence
intervals were greater than 1); the greatest difﬁculty was observed
among patients who reported severe OA. Pairwise comparisons between
OA severity levels showed that differences in functional abilities were
statistically signiﬁcant (p < 0.05). Decreases in patient-reported health
status with increasing OA severity were also observed on the EQ-5D
health state VAS, and the health state index; 0.77, 0.62, and 0.30 for
mild, moderate, and severe OA, respectively (p < 0.0001 for all pairwise
comparisons). Among the 425 patients who were employed, the percent
of OA-related impairment of work and activity increased at greater OA
severity levels after adjusting for age and gender; higher costs resulting
from lost productivity were also observed with increasing OA severity
(p < 0.0001 for pairwise comparisons).
Conclusions: Patient-reported OA severity was associated with other
patient-reported outcomes, including productivity, and these outcomes
were most impacted in patients with severe OA. This method provides
an accurate and tangible assessment of patient’s perceptions of their
disease, and may be of beneﬁt in the clinical setting when choosing
treatment options for management of OA.
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Purpose: Osteoarthritis (OA) is characterized by joint pain, stiffness,
and inﬂammation and can be associated with a signiﬁcant number
of comorbid conditions. In this retrospective longitudinal study, we
estimated the rate of hip and knee replacement surgery in patients
with OA and characterized joint replacement, pain medication treatment
patterns, and concomitant gastroprotective agent (GPA) use.
Methods: Data were enrollment information and medical and pharmacy
claims data from a large, national US health plan. The study population
was adult (age ≥18 years) commercial health plan enrollees newly
diagnosed with OA during the identiﬁcation period 1/1/2000–4/30/2009.
Patients had ≥2 medical claims with primary OA diagnoses (ICD-9-CM
715.xx, 721.0, 721.2, 721.3, 721.90) ≥30 days apart in the identiﬁcation
period; the index date was the date of the ﬁrst OA diagnosis. Patients
had 1 year of pre-index continuous enrollment with no chronic use of
NSAIDs, COX-2 inhibitors (coxibs), or oral opioids, and ≥1 year of post-
index enrollment. Outcomes included hip and knee replacement surgery
and pain medication use. Demographics, comorbidities, and Charlson
Comorbidity Index (CCI) score were measured. Data were analyzed
descriptively.
Results: Of 193,829 newly diagnosed patients with OA, 57% were
female and 43% were male. Patients whose ﬁrst observed chronic pain
medication use (index pain medications) were strong opioids appeared to
have a higher mean CCI score, 1.16, compared with those with NSAIDs,
coxibs, and weak opioid index pain medications (0.53–0.83). Patients
in the youngest (18–44) and oldest (75+) age groups appeared to be
more likely to have an opioid (35.7% and 34.9% respectively) as their
index pain medication compared with patients in the middle age groups
(45–54 yrs: 24.5%, 55–64 yrs: 19.9%, 65–74 yrs: 24.0%). The incident
rates of hip or knee replacement per person-year appeared to be higher
for those patients with opioids as their index pain medications (0.0663,
weak opioids; 0.0801, strong opioids; 0.0464, NSAIDS; 0.0548, coxibs).
The mean time from index pain medication to ANY joint replacement
appeared shorter for patients whose index pain medications were opioids
(106 days, weak opioids; 28 days, strong opioids; 320 days, nonselective
NSAIDs; 479 days, coxibs). Only 18% of patients prescribed NSAIDs were
co-prescribed a GPA.
Conclusions: The data from this study indicate speciﬁc patterns of
relationships between the index diagnosis of OA, joint replacement, pain
medication treatment, age, and concomitant GPA use. These data may
be important in reﬁning contemporary treatment guidelines, educating
physicians in appropriate care paths, and may warrant exploration of
potential unmet needs in the management of chronic pain in OA.
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Purpose: Osteoarthritis (OA) is a degenerative joint disease that is
characterized by cartilage destruction and bone changes, occasionally
accompanied by synovial inﬂammation. A major objective for OA research
is the conceptualization and development of early diagnostic strategies.
The discovery of protein biomarker panels for early diagnosis, therapeutic
purposes and management in several diseases is an area of interest
in medicine. In the present work we have quantitatively screened
differential proteins in sera and cartilage from patients suffering OA
at diverse stages. To attain this objective, a quantitative proteomics
approach has been followed, which is based on peptide differential
